Fig. 2: AFM28 efficiently directs allogeneic NK cells to CD123+ blasts in AML and HR-MDS patient BMMC samples. | Nature Communications

Fig. 2: AFM28 efficiently directs allogeneic NK cells to CD123+ blasts in AML and HR-MDS patient BMMC samples.

From: The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS

Fig. 2: AFM28 efficiently directs allogeneic NK cells to CD123+ blasts in AML and HR-MDS patient BMMC samples.The alternative text for this image may have been generated using AI.

BMMC samples derived from AML and MDS patients were treated with 0–500 pM of AFM28, a non-targeting control (RSV/CD16A) or an Fc-enhanced anti-CD123 IgG antibody for 24 h in the presence of IL-2-preincubated allogeneic healthy donor NK cells, all derived from different donors, at a 1:1 E:T ratio. Analysis was performed using flow cytometry. Blasts were defined as viable/CD45low/CD34+ or CD33+/CD38+/CD123+ cells. The gating strategy is shown in Supplementary Fig. 2A. Cell counts of 0 pM treatment were set to baseline. A–D Concentration-dependent lysis of blasts from AML (A, B, n = 10) or MDS (C, D, n = 5) patients by AFM28 compared to RSV/CD16A. E–H Concentration-dependent lysis of blasts from AML patients with low (E, F, n = 5) or high (G, H, n = 5) CD64 MFI by AFM28 compared to an Fc-enhanced anti-CD123 IgG antibody. Data in (A, C, E and G) are represented as mean ± SD. Data in (B, D, F and H) were analyzed using two-way ANOVA and Šídák’s multiple comparisons test. MFI median fluorescence intensity; SD standard deviation.

Back to article page